ASCENTAGE-B(06855) granted 1.3045 million restricted stock units and 736,600 stock options.

Astellas Pharma-B (06855) announces that as of the date of this announcement, a total of 1.3045 million restricted share units have been granted to 146 selected individuals under the 2022 Restricted Share Unit Plan, equivalent to 1.3045 million shares of stock (further granted in 2022). As of the date of this announcement, a total of 736,000 stock options have been granted to 34 recipients under the post-initial public offering stock option plan, which can be exercised to subscribe for a total of 736,000 shares of the company's common stock, subject to acceptance by the recipients of the stock options.